biotech investing Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
biotech investing Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
biotech investing Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
biotech investing Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
biotech investing Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
biotech investing Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab in Osteogenesis Imperfecta
biotech investing Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate HighlightsÂ
VanadiumCorp Updates Vanadium Énergie Nordique with Independent Assessment of Electrolyte Pilot Plant; Evaluates Recommissioning and Partnership Opportunities
